The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Adalimumab with or without Methotrexate in Juvenile Rheumatoid Arthritis
Open accessAbstract
BACKGROUND: Tumor necrosis factor (TNF) has a pathogenic role in juvenile rheumatoid arthritis. We evaluated the efficacy and safety of adalimumab, a fully human monoclonal anti-TNF antibody, in children with polyarticular-course juvenile rheumatoid arthritis. METHODS: Patients 4 to 17 years of age with active juvenile rheumatoid arthritis who had previously received treatment with nonsteroidal antiinflammatory drugs underwent stratification according to methotrexate use and received 24 mg of adalimumab per square meter of body-surface area (maximum dose, 40 mg) subcutaneously every other week for 16 weeks. We randomly assigned patients with an American College of Rheumatology Pediatric 30% (ACR Pedi 30) response at week 16 to receive adalimumab or placebo in a double-blind fashion every other week for up to 32 weeks. RESULTS: Seventy-four percent of patients not receiving methotrexate (64 of 86) and 94% of those receiving methotrexate (80 of 85) had an ACR Pedi 30 response at week 16 and were eligible for double-blind treatment. Among patients not receiving methotrexate, disease flares (the primary outcome) occurred in 43% of those receiving adalimumab and 71% of those receiving placebo (P=0.03). Among patients receiving methotrexate, flares occurred in 37% of those receiving adalimumab and 65% of those receiving placebo (P=0.02). At 48 weeks, the percentages of patients treated with methotrexate who had ACR Pedi 30, 50, 70, or 90 responses were significantly greater for those receiving adalimumab than for those receiving placebo; the differences between patients not treated with methotrexate who received adalimumab and those who received placebo were not significant. Response rates were sustained after 104 weeks of treatment. Serious adverse events possibly related to adalimumab occurred in 14 patients. CONCLUSIONS: Adalimumab therapy seems to be an efficacious option for the treatment of children with juvenile rheumatoid arthritis. (ClinicalTrials.gov number, NCT00048542.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moher, D. (2001) · JAMA · doi:10.1001/jama.285.15.1987 · Cited by 2,545
Ravelli, A., & Martini, A. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60363-8 · Cited by 1,993
Self-citationBreedveld, F. C., Weisman, M. H., Kavanaugh, A. F., Cohen, S. B., Pavelka, K., Vollenhoven, R. V., Sharp, J., Perez, J. L., & Spencer‐Green, G. T. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21519 · Cited by 1,785
Weinblatt, M. E., Keystone, E. C., Furst, D. E., Moreland, L. W., Weisman, M. H., Birbara, C. A., Teoh, L. A., Fischkoff, S. A., & Chartash, E. K. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10697 · Cited by 1,757
Etanercept in Children with Polyarticular Juvenile Rheumatoid Arthritis
Lovell, D. J., Giannini, E. H., Reiff, A., Cawkwell, G. D., Silverman, E. D., Nocton, J. J., Stein, L. D., Gedalia, A., Ilowite, N. T., Wallace, C. A., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200003163421103 · Cited by 1,246
Self-citationKeystone, E. C., Kavanaugh, A. F., Sharp, J. T., Tannenbaum, H., Hua, Y., Teoh, L. S., Fischkoff, S. A., & Chartash, E. K. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20217 · Cited by 1,172
Preliminary definition of improvement in juvenile arthritis
Giannini, E. H., Ruperto, N., Ravelli, A., Lovell, D. J., Felson, D. T., & Martini, A. (1997) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199707)40:7<1202::aid-art3>3.0.co;2-r · Cited by 1,047
Self-citationvan de Putte, L. B. A., Atkins, C., Malaise, M., Sany, J., Russell, A. S., van Riel, P. L. C. M., Settas, L., Bijlsma, J. W., Todesco, S., Dougados, M., et al. (2004) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2003.013052 · Cited by 617
Giannini, E. H., Brewer, E. J., Kuzmina, N., Shaikov, A., Maximov, A., Vorontsov, I., Fink, C. W., Newman, A. J., Cassidy, J. T., & Zemel, L. S. (1992) · New England Journal of Medicine · doi:10.1056/nejm199204163261602 · Cited by 588
Self-citationMaini, R. N., Breedveld, F. C., Kalden, J. R., Smolen, J. S., Furst, D., Weisman, M. H., St.Clair, E. W., Keenan, G. F., van der Heijde, D., Marsters, P. A., et al. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20159 · Cited by 514
Ruperto, N., Murray, K. J., Gerloni, V., Wulffraat, N., Feitosa De Oliveira, S. K., Falcini, F., Dolezalova, P., Alessio, M., Burgos‐Vargas, R., Corona, F., et al. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20288 · Cited by 375
Self-citationGenovese, M. C., Bathon, J. M., Fleischmann, R., Moreland, L. W., Martin, R. W., Whitmore, J. B., Tsuji, W. H., & Leff, J. A. (2005) · PubMed · Cited by 135
Cited by
Ravelli, A., & Martini, A. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60363-8 · Cited by 1,993
Self-citationBeukelman, T., Patkar, N. M., Saag, K. G., Tolleson‐Rinehart, S., Cron, R. Q., DeWitt, E. M., Ilowite, N. T., Kimura, Y., Laxer, R. M., Lovell, D. J., et al. (2011) · Arthritis Care & Research · doi:10.1002/acr.20460 · Cited by 834
Self-citationPrakken, B., Albani, S., & Martini, A. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60244-4 · Cited by 771
Self-citationWallace, C. A., Giannini, E. H., Huang, B., Itert, L., Ruperto, N., Childhood Arthritis Rheumatology Research Alliance (CARRA), Pediatric Rheumatology Collaborative Study Group (PRCSG), & Paediatric Rheumatology International Trials Organisation (PRINTO) (2011) · Arthritis Care & Research · doi:10.1002/acr.20497 · Cited by 574
Self-citationRuperto, N., Lovell, D. J., Quartier, P., Paz, E., Rubio-Pérez, N., Silva, C. A., Abud-Mendoza, C., Burgos-Vargas, R., Gerloni, V., Melo-Gomes, J. A., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60998-8 · Cited by 560
Self-citation
Metadata
- Authors
- Lovell, D. J., Ruperto, N., Goodman, S., Reiff, A., Jung, L., Jarosova, K., Nemcova, D., Mouy, R., Sandborg, C., Bohnsack, J., Elewaut, D., Foeldvari, I., Gerloni, V., Rovensky, J., Minden, K., Vehe, R. K., Weiner, L. W., Horneff, G., Huppertz, H.-I., Olson, N. Y., Medich, J. R., Carcereri-De-Prati, R., McIlraith, M. J., Giannini, E. H., & Martini, A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-08-21
- Volume
- 359
- Issue
- 8
- Pages
- 810-820
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1969936299
- Cited by
- 625
- References
- 12
- FWCI
- 25.38
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.